Cogent Biosciences will present a poster on bezuclastinib at the AAAAI Annual Meeting, focusing on long-term symptomatic benefits in NonAdvSM patients.
KALA BIO has secured $10.75 million in private placement funding from institutional investors to advance KPI-012, its lead candidate for persistent corneal epithelial defect (PCED). The company's Phase 2b CHASE trial is over 80% enrolled, with topline data expected in Q2 2025, potentially serving as one of two pivotal trials needed for BLA submission.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.